Reset Biology suggests asking the prescribing physician to consider Hunter Williams's 2026-03-31 framing: "Survodutide and mazdutide are not retatrutide. But they're not far off. And they fill important gaps that tirzepatide and semaglutide can't address." [Hunter Williams, email threadId 19d45fc334be87a7, 2026-03-31, https://open.spotify.com/episode/2IADOstRyI6FrZlNHriPJB] Hunter Williams also says, "People who escalate every 4 weeks instead of every 2 weeks are far more compliant and much better able to stay on the compound long term. Don't rush the titration." [same source]
Where they differ
Hunter Williams's older library article says, "Survodutide is retatrutide minus the GIP component (GLP plus glucagon). I don't see the point unless price wins." [library article slug peptide-qa-march-2025--e47049f7, 2026-03-29, no transcript cue timestamp available, https://library.hunterwilliamshealth.com/p/peptide-qa-march-2025--e47049f7/] Hunter Williams's newer 2026-03-31 email says, "Survodutide and mazdutide are not retatrutide. But they're not far off. And they fill important gaps that tirzepatide and semaglutide can't address." [email threadId 19d45fc334be87a7, https://open.spotify.com/episode/2IADOstRyI6FrZlNHriPJB] Hunter Williams's 2026-03-30 library video says, "cervidutide and mazutite look great. Those are basically a GLP plus a glucagon agonist, so they don't use the GIP receptor." [library video slug peptide-qa-february-2026--cba19117, 18:52, https://library.hunterwilliamshealth.com/p/peptide-qa-february-2026--cba19117/]